Early intervention in Alzheimer's disease: A health economic study of the effects of diagnostic timing

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Barnett, Jennifer H ^a,b   Lewis, Lily ^c   Blackwell, Andrew D ^a,b   Taylor, Matthew ^c  

^a CAMBRIDGE COGNITION   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cost effectiveness; Dementia; Diagnosis; Early intervention; Health economics; Treatment

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY INTERVENTION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; PALLIATIVE THERAPY; QUALITY ADJUSTED LIFE YEAR; AGE; COGNITION DISORDERS; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST;

CHOLINESTERASE INHIBITOR;

AGE FACTORS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; COST-BENEFIT ANALYSIS; EARLY MEDICAL INTERVENTION; LONGITUDINAL STUDIES; NEUROPSYCHOLOGICAL TESTS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84901443680     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-101     Document Type: Article

References (42)

1. Wimo A, Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia 2010, UK, London: Alzheimer's Disease International.
2. Prince M, Jackson J. World Alzheimer Report 2009 2009, UK, London: Alzheimer's Disease International.
3. Alzheimers Association 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011, 7:208-244. Alzheimers Association.
4. Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement 2012, 8:14-21. 10.1016/j.jalz.2011.01.002, 22265588.
5. Petersen RC. Mild Cognitive Impairment: Clinical Characterization and Outcome. Arch Neurol 1999, 56:303-308. 10.1001/archneur.56.3.303, 10190820.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269. 10.1016/j.jalz.2011.03.005, 3312024, 21514250.
7. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279. 10.1016/j.jalz.2011.03.008, 3312027, 21514249.
8. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292. 10.1016/j.jalz.2011.03.003, 3220946, 21514248.
9. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613. 10.1016/S1474-4422(03)00530-1, 14505582.
10. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010, 9:560-574. 10.1038/nrd3115, 20592748.
11. Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 2010, 31:1443-1451. 1451.e1, 10.1016/j.neurobiolaging.2010.04.036, 20541287.
12. Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR. Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease. Dement Geriatr Cogn Disord 2004, 17:42-48. 10.1159/000074081, 14560064.
13. The Brain Health Centre, powered by Ixico and Cambridge Cognition Ltd. http://www.thebrainhealthcentre.com/.
14. Geldmacher DS. Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review. Neuropsychiatr Dis Treat 2008, 4:549-555. 2526383, 18830441.
15. Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimers Dement 2012, 8:22-30. 10.1016/j.jalz.2010.07.001, 21420366.
16. Weimer DL, Sager MA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. Alzheimers Dement 2009, 5:215-226. 10.1016/j.jalz.2009.01.028, 2785909, 19362885.
17. Alzheimer's Society Mapping the Dementia Gap 2012, UK, London: Alzheimer's Society, Alzheimer's Society.
18. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord 2009, 23:306-314. 10.1097/WAD.0b013e3181a6bebc, 2787842, 19568149.
19. Song Y, Skinner J, Bynum J, Sutherland J, Wennberg JE, Fisher ES. Regional variations in diagnostic practices. N Engl J Med 2010, 363:45-53. 10.1056/NEJMsa0910881, 2924574, 20463332.
20. Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013, 185:1393-1401. 10.1503/cmaj.130451, 3826344, 24043661.
21. Lin P-J, Neumann PJ. The economics of mild cognitive impairment. Alzheimers Dement 2013, 9:58-62. 10.1016/j.jalz.2012.05.2117, 23141385.
22. Albert SM, Glied S, Andrews H, Stern Y, Mayeux R. Primary care expenditures before the onset of Alzheimer's disease. Neurology 2002, 59:573-578. 10.1212/WNL.59.4.573, 12196651.
23. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634. 10.1212/01.wnl.0000295996.54210.69, 17938373.
24. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ 2008, 179:787-793. 10.1503/cmaj.070803, 2553866, 18838454.
25. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1154-1166. 10.1212/WNL.56.9.1154, 11342679.
26. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013, 203:255-264. 10.1192/bjp.bp.113.127811, 24085737.
27. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues J-F. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005, 128(Pt 5):1093-1101.
28. Dartigues JF, Gagnon M, Barberger-Gateau P, Letenneur L, Commenges D, Sauvel C, Michel P, Salamon R. The Paquid epidemiological program on brain ageing. Neuroepidemiology 1992, 11(Suppl 1):14-18.
29. Folstein MF, Folstein SE, McHugh PR. " Mini-mental state" . A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6, 1202204.
30. Knapp M, Prince M. Dementia UK: A Report to the Alzheimer's Society on the Prevalence and Economic Cost of of Dementia in the UK 2007, London: Alzheimer's Society.
31. Curtis L. Unit Costs of Health and Social Care 2011 2011, UK: Canterbury.
32. Macdonald A, Cooper B. Long-term care and dementia services: an impending crisis. Age Ageing 2007, 36:16-22.
33. National Collaborating Centre for Mental Health Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care 2007, UK, London: The British Psychological Society, National Collaborating Centre for Mental Health.
34. Department of Health NHS Reference Costs: Financial Year 2011 to 2012 2012, UK, London: Department of Health, Department of Health.
35. Jönsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, Winblad B, Jönhagen ME, Hallikainen M, Wimo A. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 2006, 20:49-55. 10.1097/01.wad.0000201851.52707.c9, 16493236.
36. Office of National Statistics Interim Life Tables, 2008-2010 2011, http://www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2008-2010/index.html, Office of National Statistics.
37. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013, 6:19-33. 10.1177/1756285612461679, 3526946, 23277790.
38. Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease-a simulation study. Curr Alzheimer Res 2013, 10:207-216. 10.2174/1567205011310020011, 23036018.
39. Gervès C, Chauvin P, Bellanger MM. Evaluation of full costs of care for patients with Alzheimer's disease in France: The predominant role of informal care. Health Policy 2014, 116:114-122. 10.1016/j.healthpol.2014.01.001, 24461717.
40. Gillespie P, O'Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A. The effects of dependence and function on costs of care for Alzheimer's disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry 2013, 28:256-264. 10.1002/gps.3819, 23386588.
41. Schneider N, Yvon C. A review of multidomain interventions to support healthy cognitive ageing. J Nutr Health Aging 2013, 17:252-257. 10.1007/s12603-012-0402-8, 23459978.
42. Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement 2011, 7:318-327. 10.1016/j.jalz.2010.09.001, 21575872.